Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
Date:3/12/2009

Keryx to Host Investor Conference Call on Friday, March 13, 2009 at 8:30am EDT

NEW YORK, March 12 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2008.

At December 31, 2008, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $15.5 million, as compared to $62.4 million at December 31, 2007. In addition, at December 31, 2008, the Company had $7.2 million of auction rate securities which are classified as long-term investments.

The net loss for the fourth quarter ended December 31, 2008 was $3,807,000, or $0.08 per share, compared to a net loss of $29,261,000, or $0.67 per share, for the comparable quarter in 2007, representing a decrease in net loss of $25,454,000. The decrease in net loss was primarily attributable to a $14,076,000 decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $7,013,000 and $2,735,000 decrease in research and development expenses related to KRX-0401 and Zerenex, respectively, a $1,385,000 decrease in other selling, general and administrative expenses, and a $562,000 decrease in non-cash compensation expense related to equity incentive grants, partially offset by a $1,011,000 decrease in interest and other income (expense), net.

The net loss for the year ended December 31, 2008 was $52,881,000, or $1.18 per share, compared to a net loss of $90,062,000, or $2.07 per share, for the year ended December 31, 2007, represe
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Analyzing a puzzling multisystem disorder in ... syndrome, shedding light on key biological processes during ... to help caregivers manage the disorder, and may ... "This syndrome illuminates a very important pathway in ... controls many other genes," said study leader ...
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. ... in the development of biosimilar therapeutics, today announced ... Barclays Global Healthcare Conference in Miami, FL at the Loews ... chief executive officer of Pfenex, will provide an ... strategy on March 12th at 9:00 am ET. A live audio ...
(Date:3/2/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that it will release fourth quarter ... Tuesday, March 10, 2015 after the close of the ... call and webcast on Tuesday, March 10, 2015 at ... the results and recent corporate developments. For ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 ... newly formed alliance with Shenzhen HANK Bioengineering Co., ... Ph.D. The alliance will establish a stem cells ... Province, China in September 2015. , Shenzhen HANK ... Zhang, an award-winning scientist, microbiologist and virologist, to ...
Breaking Biology Technology:New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 2New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 4Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3
... 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ) ... of its Board of Directors approved the grant of inducement ... common stock to 7 new employees. (Logo: ... price per share equal to $11.83, the fair market value ...
... the quest to form perfectly smooth single-molecule layers of ... at the U.S. Department of Energy,s Brookhaven National Laboratory ... frozen at a temperature where the bulk material is ... extending from organic solar cells to biosensors, and understanding ...
... March 31, 2011 BioSpace launched the ... sciences companies in The Research Triangle Park and across North ... more than 10 life science employers. Each campaign participant,s logo ... that is promoted online and at industry events or ...
Cached Biology Technology:Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Expanding the degrees of surface freezing 2BioSpace Highlights North Carolina's Life Science Regions 2
(Date:3/2/2015)... JOSE, Calif. , March 2, 2015 /PRNewswire/ ... the leading developer of human interface solutions, today ... technology that is designed to enable rapid and ... Natural ID™ module for gaming is a turnkey ... ODMs the ability to quickly integrate fingerprint ID ...
(Date:3/2/2015)... Ala. , March 2, 2015  Businesses ... processing. Data protection company Tharon Rankins Enterprises has ... that provides an ultra-safe way for businesses to ... their financial transactions. Beconux is ... Tharon Rankins Enterprises. Functioning similarly to an ATM ...
(Date:3/2/2015)... March 2, 2015   Neurotechnology , a provider ... the SentiGaze Software Development Kit (SDK). The ... that use off-the-shelf webcams to track eye movements and ... a monitor. Heatmaps can be used for applications such ... online advertising. The SDK can also be used to ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Personal Data Protection Company Launches New Product 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... called microRNAs, only 19 to 21 nucleotides in length, ... genes. They do this by specifically binding to and ... for conveying the information from genes to the cellular ... building blocks of the body. Several hundred species of ...
... team of Canadian researchers, lead by Dr. Susan George ... and Mental health (CAMH), discovered a distinct dopamine signalling ... types of dopamine receptors, this novel target may have ... Published in the Proceedings of the National Academy of ...
... study sheds new light on the role of carbon dioxide ... that instead of sinking, carbon dioxide is often consumed by ... dimly lit area 100 to 1,000 meters below the surface. ... it can be stored and prevented from re-entering the atmosphere ...
Cached Biology News:Killing the messenger RNA -- But which one? 2New dopamine brain target discovered 2Ocean's 'twilight zone' may be a key to understanding climate change 2
... secretion of cytoplasmic granules, is a ... of leukocytes (e.g. basophils, neutrophils, eosinophils, ... histamine, these secretory granules contain many ... and many proteases (Hallgren, 2001). Tryptase, ...
... Processing Service enables scientists who do not have ... software to have their biological samples tested for ... as easy as 1-2-3 Chose the ... samples from the S&S antibody menu. Send ...
... This exceptionally sensitive nucleic acid gel stain ... low background in gels, making it ideal for ... standard UV transilluminators. SYBR Green I nucleic ... in capillary electrophoresis, real-time PCR assays and bandshift ...
... cross-linking techniques are defined by the author ... Wong. This valuable hardcover guide includes hundreds ... application references. More than 300 pages detail ... conjugate preparation from selection and design ...
Biology Products: